Cargando…

Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation

Atrial fibrillation (AF) is associated with an increased risk of thromboembolism, and is the most prevalent factor for cardioembolic stroke. Vitamin K antagonists (VKAs) have been the standard of care for stroke prevention in patients with AF since the early 1990s. They are very effective for the pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huber, K, Connolly, S J, Kher, A, Christory, F, Dan, G-A, Hatala, R, Kiss, R G, Meier, B, Merkely, B, Pieske, B, Potpara, T, Stępińska, J, Klun, N Vene, Vinereanu, D, Widimský, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2013
Materias:	Cardiovascular
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712459/ https://www.ncbi.nlm.nih.gov/pubmed/23557519 http://dx.doi.org/10.1111/ijcp.12147

Ejemplares similares

FDA committee unanimously recommends approval of dabigatran etexilate for stroke prevention in atrial fibrillation
por: J, Aalbers, et al.
Publicado: (2010)

Population pharmacokinetic analysis for dabigatran etexilate in Chinese patients with non-valvular atrial fibrillation
por: Liu, Ya-ou, et al.
Publicado: (2022)

The Discovery of Dabigatran Etexilate
por: van Ryn, Joanne, et al.
Publicado: (2013)

Dabigatran etexilate tetrahydrate
por: Liu, Hong-Qiang, et al.
Publicado: (2012)

The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients
por: Ellis, Christopher R, et al.
Publicado: (2013)

New options with dabigatran etexilate in anticoagulant therapy
por: Maegdefessel, Lars, et al.
Publicado: (2010)

Dabigatran-etexilate: Lack of efficacy: case report
Publicado: (2021)

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation
por: Kansal, Anuraag R, et al.
Publicado: (2012)

Exposure Response Supports Therapeutic Drug Monitoring for Dabigatran Etexilate in Patients with Atrial Fibrillation
por: Simpson, Bryan H., et al.
Publicado: (2019)

The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency
por: Gribkova, Irina V., et al.
Publicado: (2016)

Recovery of Visual Function after Administration of Dabigatran Etexilate
por: Schönfeld, Carl-Ludwig, et al.
Publicado: (2014)

Dabigatran etexilate: Cholestatic liver injury: case report
Publicado: (2021)

Choice of Renal Function Estimator Influences Adverse Outcomes with Dabigatran Etexilate in Patients with Atrial Fibrillation
por: Simpson, Bryan H., et al.
Publicado: (2018)

The effects of dabigatran etexilate on fracture healing in rats: An experimental study
por: Kerimoglu, Servet, et al.
Publicado: (2015)

Hemopericardium and Cardiac Tamponade in a Patient Treated with Dabigatran Etexilate
por: Kızılırmak, Filiz, et al.
Publicado: (2016)

Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile
por: Clemens, Andreas, et al.
Publicado: (2012)

Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate
por: Bellamy, L, et al.
Publicado: (2009)

Anticoagulation efficacy of dabigatran etexilate for left atrial appendage thrombus in patients with atrial fibrillation by transthoracic and transesophageal echocardiography
por: Xing, Xiao Fei, et al.
Publicado: (2018)

Estimation Based on Emission Wavelength of Dabigatran Etexilate Mesylate in Bulk and Capsule Dosage Form
por: Anumolu, P. D., et al.
Publicado: (2016)

Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers
por: Härtter, Sebastian, et al.
Publicado: (2012)

What neurosurgeons need to know about dabigatran etexilate (pradax(®)/pradaxa(®)/prazaxa(®))
por: Dwyer, Christopher Michael, et al.
Publicado: (2015)

The effect of oral dabigatran etexilate on bone density, strength, and microstructure in healthy mice
por: Brent, Mikkel Bo, et al.
Publicado: (2017)

In Vitro Selection of Specific DNA Aptamers Against the Anti-Coagulant Dabigatran Etexilate
por: Aljohani, Maher M., et al.
Publicado: (2018)

Extremely Elevated International Normalized Ratio in a Patient with Dabigatran Etexilate Use
por: Memon, Waqas, et al.
Publicado: (2019)

Apixaban/dabigatran etexilate/enoxaparin sodium: Various toxicities: 8 case reports
Publicado: (2022)

Rhabdomyolysis happened after the start of dabigatran etexilate treatment: A case report
por: Zheng, Tingting, et al.
Publicado: (2022)

Oral Thromboprophylaxis Following Total Hip or Knee Replacement: Review and Multicentre Experience with Dabigatran Etexilate
por: Kendoff, D, et al.
Publicado: (2011)

Predicted effect of ticagrelor on the pharmacokinetics of dabigatran etexilate using physiologically based pharmacokinetic modeling
por: Wang, Nan, et al.
Publicado: (2020)

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses
por: Pink, Joshua, et al.
Publicado: (2011)

Design and rationale for the DIVERSITY study: An open‐label, randomized study of dabigatran etexilate for pediatric venous thromboembolism
por: Albisetti, Manuela, et al.
Publicado: (2018)

Pharmacokinetic modeling and simulation support for age‐ and weight‐adjusted dosing of dabigatran etexilate in children with venous thromboembolism
por: Röshammar, Daniel, et al.
Publicado: (2021)

Preliminary Observations on the Antihypertension Action of Dabigatran Etexilate in Patients With Nonvalvular Atrial Fibrillation: A Prospective Multicenter Single-Arm Interventional Study
por: Yamamoto, Tomohiko, et al.
Publicado: (2020)

Hospital Admissions, Costs, and 30-Day Readmissions Among Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran Etexilate or Warfarin
por: Fonseca, Eileen, et al.
Publicado: (2015)

Adverse events in patients initiated on dabigatran etexilate therapy in a pharmacist-managed anticoagulation clinic
por: Donaldson, Mark, et al.
Publicado: (2013)

Impact of Pharmacists’ audit on improving the quality of prescription of dabigatran etexilate methanesulfonate: a retrospective study
por: Shimizu, Teppei, et al.
Publicado: (2017)

Myotonic dystrophy type 1 and pulmonary embolism: successful thrombus resolution with dabigatran etexilate therapy
por: GALLINORO, EMANUELE, et al.
Publicado: (2018)

Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects
por: Duan, Jingli, et al.
Publicado: (2020)

Physiologically‐based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate
por: Farhan, Nashid, et al.
Publicado: (2021)

Facile Synthesis of Dabigatran Etexilate Mesylate, an Anticoagulant Drug, Using a Novel Synthon, N-Hexyl-4-nitrophenyl Carbonate
por: Solanki, Pavankumar V., et al.
Publicado: (2018)

South African experts comment on FDA approval of dabigatran inatrial fibrillation
por: E, Klug, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_niiov2glpomhjgpeito2392kij